Trials / Recruiting
RecruitingNCT04685226
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
A Multicenter, Nonrandomized, Open-Label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 310 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors
Detailed description
Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-723 | ICP-723 is a white, round, uncoated table |
Timeline
- Start date
- 2020-09-27
- Primary completion
- 2028-01-25
- Completion
- 2028-02-25
- First posted
- 2020-12-28
- Last updated
- 2025-09-02
Locations
24 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04685226. Inclusion in this directory is not an endorsement.